N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)

Sponsor: Federal University of Minas Gerais • ClinicalTrials.gov ID: NCT06917001

Registry updated: 2026-09-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are: Is Resomelagon safe to use in patients with Dengue? Is Resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) Participants will be allocated to Resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.

Interventions

  • Resomelagon (Drug)
    Resomelagon 100mg, orally, once daily.
  • Placebo (Drug)
    Placebo
  • Standard Treatment (Other)
    Hydration and symptomatic therapy as indicated for Dengue fever.

Eligibility criteria

Inclusion Criteria: * Patients who are 18 to 65 years old; * Able to understand study procedures and give informed consent; * Presents with more than 36 and less than 84h since symptoms onset; * Symptoms compatible with dengue infection (fever, myalgia, arthralgia, headache or conjunctivitis) with positive antigen test or polymerase chain reaction test. Exclusion Criteria: * Has any comorbidity which is perceived as significant by the investigator; * Significant laboratory abnormalities discovered at triage: Hemoglobin \<10g/dL; Platelet count \< 50.000/microL; alanine transaminase \> 3x upper limit of normal; Total bilirubin \>1,5 x upper limit of normal; glomerular filtration rate \< 60mls/min/1,73m2; * Contraindications or known hypersensitivity to Resomelagon; * Presents as dengue with warning signs or severe dengue at inclusion; * Currently participating in another drug clinical trial; * Clinical evidence of another infection that might explain current symptoms; * Pregnant women or women actively trying to achieve pregnancy.

Conditions

Dengue Fever

Locations

  • Clinical Research Unit — Belo Horizonte, Minas Gerais, Brazil
  • Centro Integrado de Pesquisa — São José do Rio Preto, São Paulo, Brazil
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record